Theratechnologies (TSX:TH) FCF Margin % : -10.51% (As of Feb. 2024)

View and export this data going back to 1998. Start your Free Trial

What is Theratechnologies FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Theratechnologies's Free Cash Flow for the three months ended in Feb. 2024 was C$-2.3 Mil. Theratechnologies's Revenue for the three months ended in Feb. 2024 was C$21.9 Mil. Therefore, Theratechnologies's FCF Margin % for the quarter that ended in Feb. 2024 was -10.51%.

As of today, Theratechnologies's current FCF Yield % is -9.42%.

The historical rank and industry rank for Theratechnologies's FCF Margin % or its related term are showing as below:

TSX:TH' s FCF Margin % Range Over the Past 10 Years
Min: -131.73 Med: -10.13 Max: 23.58
Current: -7.32

During the past 13 years, the highest FCF Margin % of Theratechnologies was 23.58%. The lowest was -131.73%. And the median was -10.13%.

TSX:TH's FCF Margin % is ranked better than
74.54% of 1037 companies
in the Biotechnology industry
Industry Median: -147.18 vs TSX:TH: -7.32

Theratechnologies FCF Margin % Historical Data

The historical data trend for Theratechnologies's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theratechnologies FCF Margin % Chart

Theratechnologies Annual Data

Trend

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Nov23

FCF Margin %

Get a 7-Day Free Trial

-11.09

-20.57

-25.30

-19.58

-9.17

Theratechnologies Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
FCF Margin %	Get a 7-Day Free Trial															-17.89	-20.76	25.48	-23.90	-10.51

Competitive Comparison of Theratechnologies's FCF Margin %

For the Biotechnology subindustry, Theratechnologies's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Theratechnologies's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theratechnologies's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Theratechnologies's FCF Margin % falls into.

Theratechnologies FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Theratechnologies's FCF Margin for the fiscal year that ended in Nov. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Nov. 2023 )	/	Revenue (A: Nov. 2023 )
	=	-10.275	/	112.074
	=	-9.17 %

Theratechnologies's FCF Margin for the quarter that ended in Feb. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Feb. 2024 )	/	Revenue (Q: Feb. 2024 )
	=	-2.306	/	21.933
	=	-10.51 %

Theratechnologies FCF Margin % Related Terms

Thank you for viewing the detailed overview of Theratechnologies's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Theratechnologies (TSX:TH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theratechnologies Inc (TSX:TH) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

THTX:USA TQ80:Germany

Address

2015, rue Peel, 11e etage, Montreal, QC, CAN, H3A 1T8

Website

https://www.theratech.com

Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States.